A recent article in the NY Times raises the question about the ethics of conducting clinical trials outside the US when these studies are meant to gather evidence for drug approval in the country.
The article which was written by several Duke University researchers and was published in the New England Journal of Medicine discusses how medication that is intended for the wealthy should not be tested on people in developing countries. The report questions whether or not testing drugs in developing countries is even relevant to American patients.
What are your thoughts?
Search This Blog
Blog Archive
-
▼
2009
(141)
-
▼
February
(16)
- February Edition of Partnerships with CROs LinkedI...
- Unethical Clinical Trial Outsourcing
- New regulations from the Indian government
- Raising alarms, study sees trials migrating abroad
- Is Outsourcing of Clinical Trials Faulty?
- How to rescue a clinical trial
- Pfizer Plans to Disclose Payments Made to Clinical...
- Quintiles opens up Phase I Unit in India
- Microdosing could be a win/win for pharma, CROs
- PPD Extends its Reach to Eastern and Central Europe
- NIH Awards University of Texas $1.8M in Research G...
- Covance Opens Offices in Ukraine, Slovakia and Israel
- Covance expands into Eastern Europe and Middle East
- India to Conduct 5% Global Clinical Trials by 2012
- Executives are on the Move in the Outsourcing Indu...
- PRA International expands into southwest Asia
-
▼
February
(16)
No comments:
Post a Comment